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Possible relationship of monocyte chemoattractant protein-1 Most of the human and experimental glomerular dis-
with diabetic nephropathy. eases associated with sclerosis are characterized by the
Background. Monocyte chemoattractant protein-1 (MCP-1) infiltration of macrophages into the glomerulus in the
is a specific chemokine to recruit and activate monocytes from early stages of the disease, before the development ofthe circulation to inflammatory site. In diabetic nephropathy,
extracellular matrix expansion and glomerulosclerosissimilar to other glomerulonephropathies, infiltration and acti-
[1, 2]. Monocytes/macrophages could cause structuralvation of monocytes/macrophages in glomerulus have been im-
damage through the release of proteolytic enzymes [3]plicated in the development of glomerular injury. The aim of the
present study was to examine a possible relationship of MCP-1 and oxygen radicals [4], glomerular remodeling by the
with diabetic nephropathy and to investigate the role of gly- release of growth factors [3, 5], or glomerular functional
cated albumin (Gly-Alb) as well as high concentration of glu- alterations via the elaboration of cytokines [6] and eicosa-
cose (HG) on MCP-1 production by cultured human mesangial noids [7]. Monocyte chemoattractant protein-1 (MCP-1),cells.
a specific chemoattractant for monocytes [8–11], is impli-Methods. MCP-1 in serum or urine and urinary albumin
cated in recruiting and activating monocytes/macro-(Alb) as well as several clinical parameters such as plasma
phages to the glomerulus in proliferative glomerular dis-glucose, serum Gly-Alb, and hemoglobin A1c (HbA1c) were
measured after overnight fasting in 16 control subjects and 54 eases. Namely, human and rodent mesangial cells can
diabetic patients. The relationships between the levels of uri- synthesize MCP-1 in response to several factors thought
nary Alb and urinary or serum MCP-1 and also between the to be involved in glomerular injury, such as interleukin-1,
values of respective clinical parameter and urinary MCP-1 lev-
tumor necrosis factor-a, low-density lipoproteins, immuneels were analyzed. Next, using cultured human mesangial cells,
complexes, interferon, and thrombin [12–17]. A recentwe investigated the role of Gly-Alb and/or HG on the gene
study demonstrated that biologically active MCP-1 is pres-and protein expression of MCP-1.
Results. Urinary levels (ng/g creatinine), but not serum lev- ent in the urine of patients with various glomerular dis-
els, of MCP-1 increased in accordance with the extent of albu- eases, including diabetic nephropathy, and also that the
minuria. In all subjects, there were significant correlations be- urinary levels of MCP-1 correlate with both the extent of
tween the urinary levels of Alb and MCP-1 (r 5 0.746, P , proteinuria and the number of glomerular macrophages0.0001) and between the levels of serum Gly-Alb and urinary
[18]. Potential roles of MCP-1 and other chemokines thusMCP-1 (r 5 0.475, P , 0.0001). In cultured human mesangial
have been proposed on the initiation and progression ofcells, the gene and protein expression of MCP-1 was dose and
glomerulonephropathies [19]. This assumption may betime dependently up-regulated by Gly-Alb. HG slightly but
significantly stimulated MCP-1 expression. The combination applied to diabetic nephropathy because monocytes/
of Gly-Alb and HG showed the greatest stimulation in more macrophages infiltration has been observed in glomeru-
than an additive manner on MCP-1 production. lus in human and experimental diabetes [20–22].
Conclusions. This study suggests that facilitated MCP-1 pro-
Hyperglycemia is generally believed to be a majorduction by mesangial cells in diabetic milieu contributes to the
contributing factor to the development of diabetic com-initiation and progression of diabetic nephropathy.
plications. Nonenzymatic glycation of a wide range of
proteins, including serum albumin (Alb), occurs when
glucose concentrations rise [23]. Thus produced, Ama-Key words: glycated albumin, mesangial cells, chemokine, inflamma-
tion, hyperglycemia. dori adducts are the prominent form of circulated pro-
teins in vivo when compared with advanced glycationReceived for publication May 10, 1999
end products, and their concentrations are significantlyand in revised form January 10, 2000
Accepted for publication March 15, 2000 increased in diabetic patients during hyperglycemia [24].
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proteins on the pathogenesis of diabetic nephropathy years) with macroalbuminuria (.300 mg Alb/g Cr). Pro-
files of the control group and diabetic groups are shownhas been proposed [25]. In human and experimental
glomerular diseases such as acute glomerulonephritis in Table 1.
and chronic progressive glomerular sclerosis, one key
Collection of specimens and clinical examinationsfeature is the proliferation of glomerular mesangial cells
[1, 26, 27]. It is still controversial, however, whether Urine and venous blood were collected after overnight
fasting. Serum or urine samples for determination ofproliferation of mesangial cells is important in the patho-
genesis of diabetic nephropathy [1, 20, 26, 28]. Some MCP-1 or Alb obtained after centrifugation were, re-
spectively, stored at 2208C until assayed. Plasma levelsevidence suggests that proliferation of mesangial cells
can be found in the very early stages [20], but not in later of glucose and creatinine levels in serum or urine were
measured using an automatic analyzer (HITACHI 7450;stages in which the glomerular lesion is characterized by
expansion of the mesangial matrix, leading to encroach- Hitachi, Tokyo, Japan). Serum levels of Gly-Alb and
hemoglobin A1c (HbA1c) levels were determined byment of cellular elements and loss of filtration area and
thickening of the peripheral capillary basement mem- high-performance liquid chromatography.
brane [28]. Nonenzymatically glycated albumin (Gly-
Cell cultureAlb) has been reported to inhibit the cell growth and to
stimulate the synthesis and gene expression of type IV Normal human mesangial cells were obtained from
Clonetics (Bethesda, MD, USA) and cultured in CCMDcollagen and fibronectin in mesangial cells [29, 30]. Fur-
thermore, mesangial expansion observed in a rodent 180 medium containing 5% heat-inactivated fetal bovine
serum (FBS), 100 mg/mL piperacillin, and 100 mg/mLmodel of genetic diabetes can be significantly attenuated
by injecting antibodies selectively reacting with Amadori streptomycin with 5% CO2 in humidified atmosphere at
378C. Cells were passaged with ethylenediaminetetraace-adducts [31]. Recently, human serum Gly-Alb has been
reported to facilitate MCP-1 production in human retinal tic acid (EDTA) trypsin and were used for experiment
at passages 6 through 10. The cells were seeded into 48-pigmented epithelial cells and corneal keratinocytes
[32, 33]. In human mesangial cells, HG has been already well plates (0.2 mL/well) or 60 mm dishes (2 mL/dish)
in the medium with 5% FBS until confluence and thenreported to facilitate MCP-1 production [34], but it has
not yet been reported whether Gly-Alb may promote cultured in the medium containing 0.5% FBS for 96
hours before experiments. All experiments were per-its production.
In the present study, we aimed to clarify the correla- formed in the fresh medium with 0.5% FBS by adding
various reagents.tions of MCP-1 levels in urine and serum with the urinary
levels of Alb as an index of nephropathy and with several
Analysis of mRNA levels for MCP-1 by reverseclinical parameters in normal and diabetic subjects, and
transcription-polymerase chain reactionnext to examine the effects of Gly-Alb as well as HG
on the gene and protein expression of MCP-1 in cultured RNA was extracted from mesangial cells in a 60 mm
dish using a modified guanidinium isothiocyanate methodhuman mesangial cells.
(Isogen, Wako, Japan). Reverse transcriptase-polymerase
chain reaction (RT-PCR) was performed according to
METHODS
standard methods using a DNA PCR kit (Perkin Elmer
Subjects Cetus, Norwalk, CT, USA). Briefly, the first-strand cDNA
was synthesized using random primers and M-MLV re-Sixteen normal subjects (C, 14 men and 2 women aged
50.1 6 8.3 years; mean 6 SD) and 54 diabetic patients verse transcriptase (Promega, Madison, WI, USA), fol-
lowed by PCR amplification using synthetic gene primerswere studied. Informed consent was obtained from each
subject. All patients had normal serum creatinine levels specific for human MCP-1 [35] and human glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) [36] as re-(#114.9 mmol/L) and were divided into three groups
according to the degrees of albuminuria. Diabetic sub- ported elsewhere. The primers used were MCP-1 forward
25-mer, 59-TCGCTCAGCCAGATGCAATCAATGC-39;group-0 (D0) consisted of 36 patients [32 non–insulin-
dependent diabetes mellitus (NIDDM) and 4 insulin- MCP-1 reverse 24-mer, 59-CCCAGGGGTAGAACT
GTGGTTCAA-39; GAPDH forward 26-mer, 59-TGAAdependent diabetes mellitus (IDDM) patients; 19 men
and 17 women aged 54.4 6 14.4 years] with normoalbum- GGTCGGAGTCAACGGATTTGGT-39; and GAPDH
reverse 24-mer, 59-CATGTGGGCCATGAGGTCCACinuria [#30 mg Alb/g creatinine (mg Alb/g Cr)]. Sub-
group-1 (D1) consisted of nine patients (8 NIDDM and CAC-39. PCR amplification was performed for 30 cycles
as reported previously [35]. PCR products were electro-1 IDDM patients; 7 men and 2 women aged 62.2 6 10.4
years) with microalbuminuria (,30 to #300 mg Alb/g phoresed on a 1.5% agarose gel containing ethidium
bromide and visualized by ultraviolet-induced fluores-Cr). The third subgroup (D2) consisted of 9 patients (9
NIDDM patients; 4 men and 5 women aged 52.0 6 13.2 cence. PCR reactions resulted in the amplification of a
Banba et al: MCP-1 in diabetic nephropathy686
Table 1. Profile of control subjects and diabetic subjects divided under classification of diabetic nephropathy
Diabetic patients
Control
subjects Normoalbuminuria Microalbuminuria Macroalbuminuria
Subjects (Group) (C) (D0) (D1) (D2)
N 16 36 9 9
Gender (M/F) 14/2 19/17 7/2 4/5
NIDDM/IDDM 32/4 8/1 9/0
Age years 50.168.3 54.4614.4 62.2610.4 52.0613.2
Duration of diabetes years 9.768.2 11.767.0 13.168.7
HbA1c % 7.8561.91 8.3961.51 9.3762.07
Serum Gly-Alb % 13.761.1 23.266.2b 27.066.7b 31.16808bd
Mean BP mm Hg 96.169.5 92.569.6 92.367.7 91.2612.2
Therapy Ins/SU/diet 16/15/4 6/2/1 5/4/0
Urinary albumin mg/g Cr 1.38 4.22a 73.62c 638.3d
[0.59, 1.55] [1.55, 10.97] [32.83, 140.78] [388.80, 1279.43]
Serum creatinine lmol/L 77.8614.1 76.9617.7 76.968.8 81.3619.4
Values are means 6 SD except urinary albumin. In urinary albumin, geometric means are expressed with first quartile and third quartile in brackets. Abbreviations
are: mean BP, mean blood pressure; Ins, insulin; SU, sulfonyl urea. Comparison of mean values in age, duration of diabetes, mean BP, serum creatinine level, serum
Gly-Alb level, HbA1c level or urinary albumin levels among control (C) and diabetic groups (D0, D1 and D3) were performed by post-hoc test (Scheffe’s method)
after using one-way analysis of variance (ANOVA). Statistical analysis for urinary albumin was performed after log-transformation of assayed values.
aP , 0.05 vs. C
bP , 0.0001 vs. C
cP , 0.0001 vs. D0
dP , 0.01 vs. D1
single product of the predicted size for MCP-1 (479 bp; values less than 0.05 were taken to be statistically signifi-
cant. The Statview 4.02 program and Graphic packagedata not shown).
(Abacus Concepts Inc., Berkley, CA, USA) were used.
Chemicals and kits
Urinary Alb levels were assayed using radioimmuno-
RESULTS
assay kits with detection limit of 1.0 mg/mL purchased
Clinical studyfrom Eiken Chemical Co., Ltd. (Tokyo, Japan). MCP-1
levels in urine, serum, and culture supernatant were mea- The distribution of log-transformed values of MCP-1
in urine and serum are shown in Figure 1. The urinarysured using MCP-1 enzyme-linked immunosorbent assay
(ELISA) kits with detection limit of 5.0 pg/mL purchased mean values of MCP-1 in D1 and D2 were significantly
higher than those in C (P , 0.01 and P , 0.0001, respec-from R&D Systems, Inc. (Minneapolis, MN, USA). All
other chemicals, including human serum Gly-Alb (3.0 tively) and D0 (P , 0.05 and P , 0.0001, respectively),
although the value in D0 was slightly but not significantlynmol hexose/mol protein; endotoxin was not detected)
higher than that in C (Fig. 1A). In contrast, the serumand fatty acid free human serum Alb (as control) were
mean values of MCP-1 were not significantly differentpurchased from Sigma Chemical Co. (St. Louis, MO,
among the groups (Fig. 1B). There was a highly signifi-USA).
cant correlation between urinary levels of Alb and
Statistical analysis MCP-1 in all subjects (r 5 0.746, P , 0.0001; Fig. 1C).
Even in diabetic patients, a highly significant correlationTo facilitate statistical analysis of the clinical data, a
value equal to the detection limit was assigned to the between both parameters was also observed (r 5 0.734,
P , 0.0001). Association of urinary levels of MCP-1 withconcentrations of substances below the sensitivity of re-
spective assay. All concentrations of substances in urine several clinical characteristics such as age, duration of
diabetes, mean blood pressure, serum levels of creatininewere corrected with creatinine levels and expressed as
values/g creatinine. All values of Alb and MCP-1 in and Gly-Alb, and HbA1c levels was next studied. Mean
levels of serum Gly-Alb in all diabetic subgroups wereserum or urine were log-transformed (base 10) to achieve
near-normal distribution. All values were presented as significantly higher than in controls (P , 0.001 vs. C,
respectively), and the value in D2 was also significantlythe mean 6 SD. In vitro study values in culture superna-
tant were expressed as the mean 6 SD of four wells or higher than in D0 (P , 0.001; Table 1). Significant corre-
lations between serum levels of Gly-Alb and urinarya mean of two dishes. Comparisons of variables were
performed with a post hoc test (Scheffe’s method) after levels of MCP-1 were observed in all subjects (r 5 0.475,
P , 0.0001; Fig. 1D), even in diabetic patients (r 5 0.389,using one-way analysis of variance (ANOVA). Correla-
tions among the variables were performed by simple P , 0.005). Mean values of duration of diabetes and of
HbA1c levels were, respectively, increased in patientsregression analysis (Pearson correlation). Probability
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Fig. 1. Comparison of urinary and serum
monocyte chemoattractant protein-1 (MCP-1)
levels (A and B) in the control group (C)
and diabetic subgroups (D0, D1, and D2), and
correlations of urinary levels of MCP-1 with
urinary levels of albumin (Alb; C ) and with
serum levels of glycated albumin (Gly-Alb;
D) in all subjects. After log-transformation
(base 10) of urinary values of MCP-1 and Alb,
a comparison was performed using Scheffe’s
post hoc test after one-way analysis of vari-
ance (ANOVA). The data represented are the
mean 6 SD. Abbreviations are: C, controls;
D0, diabetics with normoalbuminuria; D1, di-
abetics with microalbuminuria; D2, diabetics
with macroalbuminuria. II P , 0.01; IIII P ,
0.0001 vs. C; H P , 0.05; HHHH P , 0.0001 vs. D0.
Simple regression analyses were performed
using the values in all subjects.
with advanced nephropathy, but no significant difference
in such parameters was observed among the diabetic
subgroups (Table 1).
In vitro study
Cultured human mesangial cells secreted small amounts
of MCP-1 in basal [5.5 mmol/L glucose (NG) 1 0.5%
FBS] condition during 24 hours of incubation. Gly-Alb
(1 mg/mL) clearly up-regulated the gene and protein ex-
pression of MCP-1 by the cells, whereas Alb (1 mg/mL)
did not (Fig. 2). The expression of MCP-1 gene and protein
was dose-dependently stimulated by Gly-Alb with the
doses ranging from 0.25 to 4 mg/mL (Fig. 3). HG (26.5
mmol/L) also slightly but significantly facilitated MCP-1
production. Furthermore, a combination of Gly-Alb and
HG showed the greatest stimulation in more than additive
Fig. 2. Time-course changes in the abundance of mRNA levels andmanner on MCP-1 gene and protein expression (Fig. 4). the amounts of MCP-1 produced by mesangial cells. Mesangial cells
Gly-Alb-induced as well as basal MCP-1 gene and protein were incubated in 60 mm dish in the 0.5% FBS containing medium
with normoglucose (d; NG, 5.5 mmol/L) with or without human serumexpression by mesangial cells cultured in either NG or
Alb (s; 1 mg/mL) or Gly-Alb (h; 1 mg/mL). Data are the mean of
HG condition was completely suppressed by either 50 two dishes. (Inset) The abundance of mRNAs for MCP-1 and GAPDH
as reference at indicated times was evaluated by RT-PCR.mmol/L pyrrolidine dithiocarbamate (PDTC) or 25 mmol/L
curcumin, in addition to actinomycin D (Act D; 1 mg/mL;
Fig. 5).
difference, however, in the serum levels of MCP-1 be-
DISCUSSION tween the respective diabetic subgroup and control
group, as well as among the diabetic subgroups. TheThe present study clearly showed that urinary levels
ratio of MCP-1 levels against Alb levels (ng MCP-1/mgof MCP-1 increased in accordance with the degree of
Alb) in urine was not fixed, but progressively declineddiabetic nephropathy, as determined by the extent of
in accordance with the degree of nephropathy [C; 77.4 6albuminuria, and moreover, that highly significant corre-
69.3, D0; 42.8 6 64.9, D1; 5.3 6 6.8, D2; 1.1 6 1.0 (mean 6lations between urinary levels of Alb and those of MCP-1
SD)], whereas the ratio of serum levels of MCP-1 againstexisted in all subjects (r 5 0.746) and even in diabetic
patients (r 5 0.735). We could not observe any significant serum levels of Alb (ng MCP-1/mg Alb) was #0.01.
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Fig. 3. Dose-dependent stimulation of MCP-1 gene and protein ex-
Fig. 4. Effects of Gly-Alb, high concentration of glucose (HG) andpression by Gly-Alb in cultured mesangial cells. Mesangial cells in 48-
the combination of both on the gene and protein expression of MCP-1well plate or 60 mm dish were incubated with graded doses of Alb (d)
by mesangial cells. Mesangial cells in a 48-well plate or a 60 mm dishor Gly-Alb (s; 0.25 to 4 mg/mL) in 0.5% FBS containing medium with
were incubated with Alb (1 mg/mL) or Gly-Alb (1 mg/mL) in 0.5%normoglucose (NG, 5.5 mmol/L). The secreted amounts of MCP-1
FBS containing medium with normoglucose (NG, 5.5 mmol/L) or highduring 48-hour incubation are represented as the mean 6 SD of four
glucose (HG, 26.5 mmol/L). The secreted amounts of MCP-1 duringindividual wells. (Inset) The abundance of mRNAs for MCP-1 and
48-hour incubation are represented as the mean 6 SD of four individualGAPDH as reference at indicated times was evaluated by RT-PCR.
wells. cP , 0.001 vs. NG in the respective condition; *P , 0.05; ***P ,
0.001 vs. basal in the respective condition; (Inset) The abundance of
mRNAs for MCP-1 and GAPDH as reference at four hours was evalu-
ated by RT-PCR.
These results probably argue against the hypothesis that
urinary levels of MCP-1 simply reflect the glomerular
filtration of circulated ones, although we could not com-
In the present study, serum levels of Gly-Alb werepletely deny a possibility that urinary MCP-1 simply re-
significantly correlated with urinary, but not serum, lev-flects a loss of yet another protein, caused by impaired
els of MCP-1 (r 5 0.475), suggesting a possible role ofglomerular permselectivity, especially in patients with
Gly-Alb on local production of MCP-1 in the kidney.overt proteinuria. Several groups have reported glomer-
Recently Gly-Alb, but not Alb, has been reported toular expression of MCP-1 in experimental and human
stimulate MCP-1 production in human retinal pigmentglomerulopathies [18, 19]. Urinary MCP-1 levels have
epithelial cells [32] and in human corneal keratinocytesbeen reported to reflect the disease activity of lupus
[33]. As observed in those cells, Gly-Alb, but not Alb,nephritis [37] and to correlate with the extent of protein-
stimulated the gene and protein expression of MCP-1 inuria and the number of glomerular macrophages in vari-
a dose- and time-dependent manner in cultured humanous glomerular diseases [18]. Furthermore, administra-
mesangial cells. HG also slightly but significantly facili-tion of antibodies to MCP-1 could decrease the extent
tated MCP-1 production by the cells, in agreement withof proteinuria, reduce glomerulosclerosis, and improve
the previous report that HG possibly facilitates MCP-1renal dysfunction in experimental crescentic glomerulo-
production by activating protein kinase C [34]. We fur-nephritis [38]. These reports suggest a potential role of
ther clarified in the present study that a combinationlocally produced MCP-1 on the initiation and progres-
of Gly-Alb and HG stimulated MCP-1 production bysion of glomerulonephropathy. Impairment of renal
mesangial cells in a more than additive manner, andfunctions in various types of glomerular diseases is asso-
also that the Gly-Alb–induced MCP-1 gene and proteinciated with tubulointerstitial changes that could be
expression by cells cultured in both NG and HG condi-caused, at least partly, by infiltrated macrophages [39].
tions was completely inhibited by PDTC, an inhibitor ofRenal proximal tubular epithelial cells (RPTECs) have
nuclear factor-kB (NF-kB) activation [43] or curcumin,been reported to produce MCP-1 in response to cyto-
an inhibitor of activator protein-1 (AP-1) binding tokines [40] and urinary proteins [41, 42]. Since tubuloin-
DNA and of NF-kB activation [44]. The promotor regionterstitial changes associated with macrophage infiltration
of the human MCP-1 gene has recently been cloned,have been observed in diabetic nephropathy [20–22],
sequenced, and shown to contain putative consensusRPTECs, in addition to mesangial cells and infiltrated
binding sites for a variety of transcription factors [45, 46].macrophages by themselves [8–10], might contribute to
the urinary excretion of MCP-1. An operation of NF-kB [46, 47] and also a cooperative
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centration of glucose; IDDM, insulin-dependent diabetes mellitus;
MCP-1, monocyte chemoattractant protein-1; NG, normoglucose;
NIDDM, non–insulin-dependent diabetes mellitus; PDTC, pyrrolidine
dithiocarbamate; RT-PCR, reverse transcription-polymerase chain re-
action; NF-kB, nuclear factor-kB; and RPTECs, renal proximal tubular
epithelial cells.
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